Abstract
Despite guideline-directed disease-modifying therapies, patients suffering from heart failure with reduced ejection fraction (HFrEF) continue to face long-term clinical sequelae. Empagliflozin, a sodium glucose co-transporter 2 inhibitor (SGLT2i), has been shown to reduce hospitalizations and deaths in patients with HFrEF. We conducted a cost-utility analysis to estimate the value of add-on empagliflozin versus usual care (UC) for HFrEF from a UK healthcare system perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
